Gunnar Sæter
- Head of research and professor; MD, PhD
- +47 22 78 14 02/ 970 31 845
August 2013
PERSONAL DETAILS:
Born: 1954.
Nationality: Norwegian.
Board Certified Speciality: Medical Oncology and Radiotherapy (1990).
Present appointment: Institute Head and Professor, Institute for Cancer Research, Oslo University Hospital (from August 2013).
Tel. +47-91502770 (switchboard)
Mobile +47 97031845
E-mail: gunnar.sater@rr-research.no
EDUCATION AND JOB APPOINTMENTS:
1979: M.D. from The Royal College of Surgeons in Ireland (Dublin).
July 1979 - Jan. 1980: House Officer, Internal Medicine, Aker Hospital, Oslo.
Jan. 1980 - Jan. 1981: Internship, Buskerud Central Hospital, Drammen, Norway (rotation through internal medicine, general surgery, gynaecology & obstetrics, paediatrics and neurology).
Jan. 1981 - July 1981: Internship, General Practice.
July 1981 - Dec. 1983: Senior House Officer and later Registrar, Dept. of Medical Oncology and Radiotherapy, The Norwegian Radium Hospital, Oslo (rotation within all tumour types).
Jan. 1984 - Oct. 1987: Research Fellow of The Norwegian Cancer Society at Dept. of Tissue Culture, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo.
Project: Experimental and Human Liver Carcinogenesis.
1984-1985: Medical Advisor, Nycomed Pharma, Oslo, Norway (part time).
Oct. 1987 - July 1988: Senior Registrar, Dept. of Internal Medicine, Ullevål Hospital, Oslo.
July 1988 - Oct. 1990: Senior Registrar, Sarcoma Division, Dept. of Medical Oncology and Radiotherapy, The Norwegian Radium Hospital, Oslo.
1989: Ph. D. degree with the thesis "Cell Proliferation and Tumour Promotion in Experimental and Human Carcinogenesis" (University of Oslo).
January 1990: Board-certified specialist in Medical Oncology and Radiotherapy.
Oct. 1990 - March 2000: Consultant Medical Oncologist and Radiotherapist, Division of Sarcoma and Urogenital Cancer, Dept. of Medical Oncology and Radiotherapy, The Norwegian Radium Hospital, Oslo.
Jan. 1993 - March 2000: Division Head, Division for Sarcomas and Urogenital Cancer, Dept. of Medical Oncology and Radiotherapy, The Norwegian Radium Hospital, Oslo.
March 2000 - June 2006: Head, Department of Medical Oncology, The Norwegian Radium Hospital, Oslo.
June 2004 - June 2006: Associate Professor of Oncology, University of Oslo.
June 2006 - Jan 2009: Chief Physician and medical Director, Ulleval University Hospital, Oslo
Jan. 2009-Jan. 2010: Medical Director, MSD Norway AS, Drammen, Norway
Jan. 2010-May 2010: Regional Research Director, MSD Scandinavia
May 2010-January 2011: Regional Director of Medical Affairs for Oncology in Europe, Canada, Middle East & Africa, MSD
January 2011 - August 2013: Global Director of Scientific Affairs, Merck Oncology, Merck Inc. (MSD)
August 2013 - current appointment: Institute Head and Professor, Institute for Cancer Research, Oslo University Hospital
HIGH LEVEL SUMMARY OF MY CURRENT & PREVIOUS WORK APPOINTMENTS:
Current Position: The comprehensive cancer center at Oslo University Hospital is one of the largest cancer centers in Northern Europe and has tightly integrated basic, translational and clinical cancer research of very high standard (very good to excellent by official international evaluation). As the Head of the Institute for Cancer Research I have the senior leadership of the basic and translational research in a brand new research facility housing approx. 350 research employees. The Institute is organized in seven research sections with approx. 35 research groups, of which most have extensive collaboration with clinical oncology. The position also involves own research (sarcoma biology and clinical research), and is combined with a 20% position as Professor of Oncology at the University of Oslo.
Most recent past position: Global Director of Scientific Affairs, Merck Oncology (Jan. 2011 - Aug. 2013).
This was a headquarter position at level of Senior Director (level Executive Committee +2), reporting to the Vice President, Global Center for Scientific Affairs (scientific body across all therapeutic areas). The position has a seat in the Merck Oncology Senior Leadership Team.
Main responsibilities:
- Management of Company interactions and collaborations with internationally leading oncology & cancer research institutions and the global scientific leaders in clinical oncology and cancer research
- Planning, execution and chairmanship of major external scientific input into the company, including global consultation meetings for pipeline strategy, compound development and further development of approved drugs
- Leader and chairmanship of the Oncology Investigator Initiated Study Program (through external collaborating institutions). Responsible for the definition of the areas of interest for the program and for the scientific review of submitted proposals.
- Bridge and promote collaboration and alignment between the scientific and commercial parts of the organization
- Secure patient focus, patient safety and medical perspective in all relevant activities.
Previous positions in Merck (MSD):
The position as Medical Director in MSD Norway (2009-2010) involved the senior leadership of all medical activities across all therapeutic areas, as well as research, regulatory affairs, compliance and pharmacovigilance. This included a considerable collaboration with The Norwegian Radium Hospital and Dept. of Oncology at UUS through the OncoNet program, and with The Norwegian Cancer Registry on the development of HPV vaccine and the effects of the HPV vaccination program on the HPV infection pattern in the population.
In this position I had 7 direct reports and the responsibility for a unit consisting of 24 people.
The position as Research Director for Scandinavia (2010) involved senior operational and strategic responsibility for all company-sponsored research projects across all therapeutic areas in Norway, Sweden, Denmark and Finland. This position involved the lead responsibility for the calibration and reorganization of all the Scandinavian research organizations following the Merck-Schering-Plough merger, and harmonization of personel, operations, routines and culture in the new organization.
In this position I had 5 direct reports (country research directors) and the responsibility for a total of 110 employees.
The position as Regional Director of Medical Affairs for Oncology (2010-2011) involved responsibility for all major research collaborations between Merck and hospitals/institutions in my region (Europe, Canada, Middle East and Africa), as well as interactions with key institutions and scientists, and a central position in forming the regional oncology strategy for the company.
Positions in University Hospital Oncology and Academia:
General aspects:
During my clinical work I have been particularly interested in the structure, cooperation and refinement of multidisciplinary teams treating cancer patients, including the vital clinical research aspects and the role of integrated laboratory and translational cancer research. The key thinking was to evolve into a Comprehensive Cancer Center (CCC), and in this context I have published improvements in outcome related to patient volume, team training and organizational refinement (Saeter et al., Int J Cancer, Suppl. 13, 52, 2002 and Aksnes et al. and Acta Oncol. Scand. 45, 38-46, 2006). The success experienced by the NRH sarcoma program contributed to a re-organization of all the clinical activity in NRH into formalized multidisciplinary teams, and during my work as Head of the department of Medical Oncology I was a significant contributor in this development.
Head of the Department of Medical Oncology at NRH in Oslo (2000-2006). NRH is one of Scandinavia's leading Comprehensive Cancer Centers. The position included the senior responsibility for clinical activity, multidisciplinary team development and clinical research in the programs with medical oncology as the dominant or main developmental treatment modality (lymphoma, sarcoma, lung cancer and testicular cancer). The position was also part of the Institution's Leadership Team.
Senior consultant and Head of the NRH Sarcoma Program (1993-2000). This included development of the multidisciplinary team, clinical program and research program, as well as a total operational responsibility. The position was also associated with the scientific and clinical leadership in the Scandinavian Sarcoma Group (SSG) with substantial international collaborative scientific activity and leadership of collaborative group clinical studies and Scandinavian treatment guidelines development (please also see the section for research activity). My work in the Radium Hospital Sarcoma Program also involved the development of a comprehensive electronic institutional database containing clinical data on all sarcoma and benign bone/soft tissue tumor patients treated at Radium hospital from 1980 onwards. This database was established in collaboration with the Norwegian Cancer Registry and is continuously being updated. During my leadership of the sarcoma program NRH was appointed the National Centre of Competence for sarcomas, and the total program activity monitored in the database forms the basis of annual report from this Centre of Competence.
Medical Director and Chief Medical Officer (2006-2009) at Ulleval University Hospital, a 1200 bed institution with all disciplines within somatic medicine and psychiatry. It is a local hospital for 200 000 of Oslo's 450 000 inhabitants, and also has an array of regional hospital tasks for the South-Eastern Health Region. The most important areas of strategic importance are severe acute illness, severe traumatology and emergency capacity for major domestic and international events. The position was the CEO's lead medical advisor and involved an overall responsibility for institutional medical strategy, prioritization, structure and quality of treatment, including the institution's strategic development. The position also had a key role in planning of the merger of several key Oslo hospitals into Oslo University Hospital (see below) and had a key role in the planning and execution of health care in Norway's South-Eastern Health Region.
RESEARCH, INCLUDING INTERNATIONAL ACTIVITIES:
Jan. 1984 - Oct. 1987: Research Fellow of The Norwegian Cancer Society at Dept. of Tissue Culture, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo.
Project: Experimental and Human Liver Carcinogenesis.
Nov. 1986 and June 1987: Guest Researcher at The National Taiwan University Hospital, Taipei, Taiwan. Project: The Cell Biology of Human Hepatocellular Carcinoma.
1989: Ph. D. degree with the thesis "Cell Proliferation and Tumour Promotion in Experimental and Human Liver Carcinogenesis" (University of Oslo).
1988 - 2000 Clinical Research Coordinator of The Scandinavian Sarcoma Group (SSG). I have had the position of international PI and study coordinator functions for 6 international cooperative studies on osteosarcoma and soft tissue sarcoma (numbers 1-5 and 8 in the list below), with principal responsibility for protocol design, study monitoring, data analysis and publication. In addition I have been Norwegian PI & study coordinator responsibility for 2 studies on Ewing's sarcoma (numbers 6 and 7 below). The position as SSG Research Coordinator has also involved a coordinator function in the bone sarcoma cooperation between the Scandinavian (SSG) and Italian (ISG) sarcoma groups.
The role in SSG also included development of the SSG Central Patient Register, a Scandinavian Sarcoma database organized within the Regional Cancer Register for South Sweden.
The studies with international Principal Investigator responsibilities have been:
1. Scandinavian multicenter osteosarcoma study SSG-II, published by Saeter et al. in J. Clin. Oncol., 9, 1766-1775, 1991.
2. Scandinavian multicenter osteosarcoma study SSG VIII, published by Smeland et al. in Eur. J. Cancer, 39, 488-494, 2003.
3. Osteosarcoma intergroup pilot study ISG/SSG I, published by Bacci et al. in J. Chemother, 14,198-206, 2002.
4. Osteosarcoma intergroup study ISG/SSG I, preliminary results presented by Smeland et al. at ASCO 2003 (Proc. ASCO, 22, 817, 2003), final paper by Ferrari et al.in J. Clin. Oncol., 23, 8845-8852, 2005.
5. Osteosarcoma intergroup study ISG/SSG II, recently closed for inclusion.
6. Scandinavian multicenter Ewing's sarcoma study SSG IV, published by Nilbert et al. in Acta Oncol. Scand., 37, 375-378, 1998.
7. Scandinavian multicenter Ewing's sarcoma study SSG IX, published by Elomaa et al. in Eur. J. Cancer, 36, 875-880, 2000.
8. Scandinavian multicenter soft tissue sarcoma study SSG X, published by Saeter et al. in Eur. J. Cancer, 33, 1551-1558, 1997.
1993 - 2000 Secretary and Scientific Coordinator, The Scandinavian Sarcoma Group: Involved responsibility for a coordinated strategy and organization of the diagnosis and treatment of bone and soft tissue tumours in Sweden, Norway, Finland, Denmark and Iceland. The position also involved advisory functions and support during the formation of National sarcoma groups in Italy, UK, Poland and Australia.
2003-2007: Member of the Advisory Board of "Framingham on Oncology" (monthly international publication).
April 2004 onwards: Faculty Member in European Society of Medical Oncology (ESMO).
Reviewer for manuscripts submitted to a multitude of national and international journals, including Eur. J. Cancer, Cancer, Hepatology, Acta Oncol. Scand., Acta Orthop. Scand. and J. Norw. Med. Assoc.
Member of EU expert evaluation panel for research applications to the EU 6th Framework Program in 2003/2004 and 2005/2006 (two successive appointments):
Appointed as an independent expert doing both remote evaluations and on-site expert panel evaluations in Brussels. In 2004 I also served as the responsible reference expert for the panel evaluating the applications to the section "Development of European Networks of Excellence to promote research into uncommon cancers in adults and children".
EU person of reference for this activity: Director Dr. Maria-Jose Vidal-Ragout.
Expert reviewer of ongoing funded EU research programs (6th Framework) in 2007/2008 (two reviews).
June 2005: Member of ESMO expert advisory panel on the plans of a merger between European Clinical Cancer Societies into one multidisciplinary organization.
May 2009: Awarded Honorary Membership of The Scandinavian Sarcoma Group.
Previous participation in clinical and translational research projects at The Norwegian Radium Hospital:
* Clinical outcome in bone and soft tissue sarcoma.
* Molecular genetic determinants of chemosensitivity and chemoresistance in bone and soft tissue sarcomas.
* The role of interferon in anti-osteosarcoma therapy: molecular mechanisms and clinical effects.
* Detection of micrometastatic disease in osteosarcoma and its value in prognostication and monitoration of treatment effect.
* Effects on treatment results of multidisciplinary team organization and its refinement.
* Long term toxicity and quality of life following successful chemotherapy in childhood and adolescence.
* Molecular characterization of peripheral nerve sheath tumours.
* Biology and clinical outcome in radiation-induced sarcomas.
* Institutional leader of the Steering group for all projects on gene therapy and vaccine development (in lung cancer, prostate cancer, melanoma and paediatric solid tumours).
* Steering group member for the institutional projects on functional genomics (microarray
technology and proteomics).
PUBLICATIONS:
84 original peer-reviewed published papers registered in PubMed.
19 review papers, book chapters and monographs.
4 other scientific publications with original data.
105 published abstracts with original data.
9 publications of other typs, including 3 public reports, official yearly reports on patient
activity, and publications intended for the public.
IN TOTAL 211 PUBLICATIONS (complete list available on request).
DEVELOPMENT OF INNOVATIVE TECHNOLOGY:
Since 1998 head of the development of a novel IT application for dosage, ordination, pharmacy production, administration and quality assurance of chemotherapy ("Cytodose"). The application electronically standardizes all chemotherapy courses, and effectuates dosage, ordination to pharmacy, pharmacy production and administration to the patient. The application is commercialized through a software company specialized in hospital software, and is currently in use in multiple oncology centres and departments in Norway and Sweden, and an European launch is forthcoming. In cooperation with the Norwegian Department of Health I have also led the development of related applications including a national database of standardized and quality assured chemotherapy course descriptions ("Cytoreg") where the course descriptions can be directly downloaded into Cytodose (available on the internet at www.oncolex.no/cytostatica). Also, a network version of Cytodose ("Cytolink") has been developed to allow on-line chemotherapy interaction between cooperating oncology institutions treating the same patient (Cytolink is currently undergoing b testing).
I am now part of a team futher developing Cytodose into a multidisciplinary treatment program giving multifunctional access to both individual patient treatment plans and protocol design for standardized patient treatment and clinical research.
MEMBERSHIP IN INTERNATIONAL RESEARCH SOCIETIES:
* The Scandinavian Sarcoma Group (SSG) (Honorary member)
* The American Association for Cancer Research (AACR)
* The European Musculo-Skeletal Oncology Society (EMSOS)
* European Osteosarcoma Intergroup (EOI)
* Connective Tissue Oncology Society (CTOS)
* European Society for Medical Oncology (ESMO)
* American Society of Clinical Oncology (ASCO)
* Nordic Association for Pediatric Hematology & Oncology (NOPHO)
LEADERSHIP EXPERIENCE WITH MERGERS AND ORGANIZATIONAL CHANGE : RE-DESIGN OF INSTITUTIONS & COMPANIES
I have considerable experience in this field as I have held core leadership positions in the following re-design processes and organizational mergers:
1. The merger between two of Oslo's university hospitals: Rikshospitalet and The Norwegian Radium Hospital in 2004-2005.
2. The subsequent merger between all three Oslo University Hospitals (Rikshospitalet, Ullevål University Hospital, Aker University Hospital) in 2005-2006.
3. The merger between Merck and Schering-Plough in 2009-2010.
HEALTH ADMINISTRATIVE QUALIFICATIONS:
* Head of the the Department of Medical Oncology, The Norwegian Radium Hospital (NRH) from March 2000 (current position).
* Head of NRH's multidisciplinary sarcoma group 1993-2000.
* Member of the Medical Advisory Board to the Director of NRH from 1988 to 1991. Secretary of the Board for 2 years.
* Secretary of Department of Health Committee for the study of the relationship between patient volume and the quality of patient care (appointed June 1992, final report published in 1993 - is also available in English).
* Chairman for Department of Health Committee for the organisation of pediatric oncology in Norway, report finalized and published 01.02.1994.
* Author of a comprehensive report to The Department of Health advising centralization of all patients with high-grade malignant bone tumours to one national centre.
* Member of the Regional Health Committee on paediatric services and genetics for Health Region II (eastern, central and southern Norway).
* Scandinavian Sarcoma Group and international research appointments (see above).
* From January 1996 appointed Norwegian Medical Association representative in The Medical Council for Life Insurance, which is a centralized board for the evaluation of complicated health status in relation to life insurance.
* Member of Regional Council for the elaboration of a Regional Plan for Cancer Care (for Southern/Eastern Norway). Published in May 2004.
* Member of the senior "Coordinating Group" during the merger negotiations and implementation between the hospitals NRH and Rikshospitalet in Oslo Jan.-June 2004.
* Member of the merged institution's "Strategic Board" from Jan. 2005.
TEACHING AND ACADEMIC APPOINTMENTS:
* Faculty Member, European Society for Medical Oncology (ESMO), from June 2004
* 2000 and updated in 2005: The author of two ESMO guidelines for the diagnosis and treatment of osteosarcoma and Ewing's sarcoma, published on the internet (www.esmo.org) and in Ann. Oncol.; Vol. 16 Suppl 1, 71-74, 2005.
* Opponent appointed by The University of Lund for the Ph.D. dissertation of Pelle Gustafsson, 1993 (Thesis: Soft Tissue Sarcoma. Epidemiology and prognosis in 508 patients).
* Clinical teaching at the University of Oslo Medical School, one half day per week (from 1988 onwards).
* Coordinator, presenter and lecturer at a vast number of national and international teaching courses, congresses etc.
* Mentorship for 5 successful Ph.D. dissertations:
Björn Skytting MD, Ph.D: "Synovial Sarcoma. A Scandinavian Sarcoma Group Project", University of Stockholm, 2000.
Clement Trovik MD, Ph.D: "Local recurrence of soft tissue sarcoma. A Scandinavian Sarcoma Group Project", University of Bergen, 2001.
Liv Hege Aksnes MD, Ph.D: "Health in long-term survivors of bone sarcoma", University of Oslo, 2009
Christoph Müller MD, Ph.D: "Novel approaches to the treatment of high-grade sarcoma", University of Oslo, 2011.
Hege Ohnstad MD, Ph.D: "Novel therapeutic strategies in sarcoma", University of Oslo 2013.
* Currently (2013) mentor for one ongoing Ph. D. project: Bodil Bjerkehagen MD: Secondary sarcomas.
* 2002: Professoral competence for Gunnar Saeter declared by the University of Oslo after evaluation by an international committee. Associate professor in Oncology at The University of Oslo from Oct. 2002.
* Appointed opponent by The University of Lund, Sweden, for the Ph.D. dissertation of Jacob Engellau, MD, in December 2004 (Thesis: Malignant Fibrous Histiocytomas of Soft Tissue).
* Keynote speaker at the world SIOP congress on pediatric oncology in Oslo (September 2004). Title: "Current challenges in Bone Sarcomas". This presentation is part of the Cure4Kids network and available on: http://www.cure4kids.org/siop/
* Invited speaker at the annual conference of Association of National Cancer Registries in Stockholm Sept. 2004. Title: Collaboration between cancer registries and clinical researchers: What have we achieved and where do we go? The case in Lymphoma and Sarcoma research.
* Member of the scientific committee for the ESMO congress in Istanbul 2006.
* Invited speaker for the "Campanacci Honorary Lecture" at the 2012 European Musculoskeletal Oncology Society (EMSOS): "Modern drug development seen from the academic and industrial perspectives: personal reflections from a hybrid".
* A vast number of lectures and presentations in national and international fora, several dozens of duties as chairman of scientific sessions etc.
* Professor of Oncology at The University of Oslo (from Aug. 2013)
Publications 2023
Evaluating comprehensive cancer networks; a review of standards and evaluation methods for care networks to inform a comparison with the OECI comprehensive cancer network standards
Acta Oncol, 62 (1), 15-24
DOI 10.1080/0284186X.2023.2170275, PubMed 36786345
Publications 2021
Analysing the attributes of Comprehensive Cancer Centres and Cancer Centres across Europe to identify key hallmarks
Mol Oncol, 15 (5), 1277-1288
DOI 10.1002/1878-0261.12950, PubMed 33734563
Publications 2020
100 European core quality standards for cancer care and research centres
Lancet Oncol, 21 (8), 1009-1011
DOI 10.1016/S1470-2045(20)30318-1, PubMed 32758458
Publications 2017
Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper
Eur J Cancer, 82, 193-202
DOI 10.1016/j.ejca.2017.04.014, PubMed 28692951
Publications 2015
Teenagers and young adults with cancer in Europe: from national programmes to a European integrated coordinated project
Eur J Cancer Care (Engl), 25 (3), 419-27
DOI 10.1111/ecc.12365, PubMed 26239724
Publications 2014
Response to preoperative chemotherapy in patients undergoing resection of pulmonary metastasis from soft tissue sarcoma - a predictor of outcome?
Acta Oncol, 53 (9), 1180-7
DOI 10.3109/0284186X.2014.899433, PubMed 24697744
Publications 2013
High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: final results of the ISG/SSG II study
Pediatr Blood Cancer, 61 (5), 840-5
DOI 10.1002/pbc.24868, PubMed 24254749
Publications 2012
Global gene expression profiling of human osteosarcomas reveals metastasis-associated chemokine pattern
Sarcoma, 2012, 639038
DOI 10.1155/2012/639038, PubMed 22518090
Publications 2010
[Syphilis and blood transfusion]
Tidsskr Nor Laegeforen, 130 (8), 839-41
DOI 10.4045/tidsskr.08.0188, PubMed 20418930
Publications 2008
Radiation-induced sarcoma: 25-year experience from the Norwegian Radium Hospital
Acta Oncol, 47 (8), 1475-82
DOI 10.1080/02841860802047387, PubMed 18607853
Publications 2007
Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up
Ann Oncol, 18 Suppl 2, ii77-8
DOI 10.1093/annonc/mdm047, PubMed 17491058
Ewing's sarcoma of bone: ESMO clinical recommendations for diagnosis, treatment and follow-up
Ann Oncol, 18 Suppl 2, ii79-80
DOI 10.1093/annonc/mdm048, PubMed 17491059
[Anticancer drug dosing--pharmacogenomic biomarkers or body surface area?]
Tidsskr Nor Laegeforen, 127 (8), 1040-4
PubMed 17457389
Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A
Int J Cancer, 121 (1), 199-205
DOI 10.1002/ijc.22643, PubMed 17354236
Publications 2006
Management of high-grade bone sarcomas over two decades: the Norwegian Radium Hospital experience
Acta Oncol, 45 (1), 38-46
DOI 10.1080/02841860500466624, PubMed 16464794
Publications 2005
Hematogenous micrometastases in osteosarcoma patients
Clin Cancer Res, 11 (13), 4666-73
DOI 10.1158/1078-0432.CCR-05-0165, PubMed 16000559
Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups
J Clin Oncol, 23 (34), 8845-52
DOI 10.1200/JCO.2004.00.5785, PubMed 16246977
Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series
Acta Oncol, 44 (5), 475-80
DOI 10.1080/02841860510029978, PubMed 16118081
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of osteosarcoma
Ann Oncol, 16 Suppl 1, i71-2
DOI 10.1093/annonc/mdi822, PubMed 15888764
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of Ewing's sarcoma of bone
Ann Oncol, 16 Suppl 1, i73-4
DOI 10.1093/annonc/mdi811, PubMed 15888765
Publications 2003
Osteosarcoma over the age of forty
Eur J Cancer, 39 (2), 157-63
DOI 10.1016/s0959-8049(02)00478-1, PubMed 12509946
Cytogenetic and molecular genetic analyses of endometrial stromal sarcoma: nonrandom involvement of chromosome arms 6p and 7p and confirmation of JAZF1/JJAZ1 gene fusion in t(7;17)
Cancer Genet Cytogenet, 144 (2), 119-24
DOI 10.1016/s0165-4608(03)00025-6, PubMed 12850374
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of osteosarcoma
Ann Oncol, 14 (8), 1165-6
DOI 10.1093/annonc/mdg336, PubMed 12881369
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of Ewing's sarcoma of bone
Ann Oncol, 14 (8), 1167-8
DOI 10.1093/annonc/mdg335, PubMed 12881370
Reply to comment on "Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders"
Eur. J. Cancer, 39 (17), 2567-2568
DOI 10.1016/j.ejca.2003.08.019
Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders
Eur J Cancer, 39 (4), 488-94
DOI 10.1016/s0959-8049(02)00747-5, PubMed 12751380
[Paclitaxel should be included in standard therapy of ovarian carcinoma]
Tidsskr Nor Laegeforen, 123 (21), 3083-4
PubMed 14618184
Publications 2002
High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study
J Chemother, 14 (2), 198-206
DOI 10.1179/joc.2002.14.2.198, PubMed 12017378
[Bone and soft tissue sarcomas treated at the Norwegian Radium Hospital 1980-99]
Tidsskr Nor Laegeforen, 122 (21), 2089-94
PubMed 12555642
Publications 2001
Monitoring referral and treatment in soft tissue sarcoma: study based on 1,851 patients from the Scandinavian Sarcoma Group Register
Acta Orthop Scand, 72 (2), 150-9
DOI 10.1080/000164701317323408, PubMed 11372946
Dedifferentiation of a well-differentiated liposarcoma to a highly malignant metastatic osteosarcoma: amplification of 12q14 at all stages and gain of 1q22-q24 associated with metastases
Cancer Genet Cytogenet, 125 (2), 100-11
DOI 10.1016/s0165-4608(00)00369-1, PubMed 11369052
Biallelic inactivation of TP53 rarely contributes to the development of malignant peripheral nerve sheath tumors
Genes Chromosomes Cancer, 30 (2), 202-6
DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1079>3.0.CO;2-5, PubMed 11135438
Computed tomography of pulmonary metastases from osteosarcoma: the less poor technique. A study of 51 patients with histological correlation
Ann Oncol, 12 (11), 1601-4
DOI 10.1023/a:1013103511633, PubMed 11822761
Local recurrence of deep-seated, high-grade, soft tissue sarcoma: 459 patients from the Scandinavian Sarcoma Group Register
Acta Orthop Scand, 72 (2), 160-6
DOI 10.1080/000164701317323417, PubMed 11372947
Publications 2000
Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide
Oncol Rep, 7 (2), 339-46
DOI 10.3892/or.7.2.339, PubMed 10671683
Five-year results in Ewing's sarcoma. The Scandinavian Sarcoma Group experience with the SSG IX protocol
Eur J Cancer, 36 (7), 875-80
DOI 10.1016/s0959-8049(00)00028-9, PubMed 10785592
Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group Register
Eur J Cancer, 36 (6), 710-6
DOI 10.1016/s0959-8049(99)00287-7, PubMed 10762742
Consequences of local recurrence of soft tissue sarcoma: 205 patients from the Scandinavian Sarcoma Group Register
Acta Orthop Scand, 71 (5), 488-95
DOI 10.1080/000164700317381199, PubMed 11186407
Publications 1999
The Scandinavian Sarcoma Group - Background, organization and the Central Register - the first 20 years
Acta Orthop. Scand., 70 285, 3-7
DOI 10.1080/17453674.1999.11744815
The Scandinavian Sarcoma Group. Background, organization and the Central Register--the first 20 years
Acta Orthop Scand Suppl, 285, 3-7
PubMed 10429614
The Scandinavian Sarcoma Group Register
Acta Orthop Scand Suppl, 285, 41-4
DOI 10.1080/17453674.1999.11744821, PubMed 10429620
Chromosome band 9p21 is frequently altered in malignant peripheral nerve sheath tumors: studies of CDKN2A and other genes of the pRB pathway
Genes Chromosomes Cancer, 26 (2), 151-60
DOI 10.1002/(SICI)1098-2264(199910)26:2<151::AID-GCC7>3.0.CO;2-A, PubMed 10469453
Extraskeletal myxoid chondrosarcoma: multimodal diagnosis and identification of a new cytogenetic subgroup characterized by t(9;17)(q22;q11)
Virchows Arch, 435 (5), 524-30
DOI 10.1007/s004280050437, PubMed 10592057
Chemotherapy in Ewing's sarcoma - The Scandinavian Sarcoma Group experience
Acta Orthop. Scand., 70 285, 69-73
DOI 10.1080/17453674.1999.11744827
Chemotherapy in Ewing's sarcoma. The Scandinavian Sarcoma Group experience
Acta Orthop Scand Suppl, 285, 69-73
PubMed 10429626
Chemotherapy in soft tissue sarcoma. The Scandinavian Sarcoma Group experience
Acta Orthop Scand Suppl, 285, 62-8
DOI 10.1080/17453674.1999.11744826, PubMed 10429625
Combined RxFISH/G-banding allows refined karyotyping of solid tumors
Hum Genet, 104 (5), 370-5
DOI 10.1007/s004390050970, PubMed 10394927
Fusion of the RBP56 and CHN genes in extraskeletal myxoid chondrosarcomas with translocation t(9;17)(q22;q11)
Oncogene, 18 (52), 7594-8
DOI 10.1038/sj.onc.1203155, PubMed 10602519
Prognostic factors in soft tissue sarcoma - A review and the Scandinavian Sarcoma Group experience
Acta Orthop. Scand., 70 285, 50-57
DOI 10.1080/17453674.1999.11744824
Prognostic factors in soft tissue sarcoma. A review and the Scandinavian Sarcoma Group experience
Acta Orthop Scand Suppl, 285, 50-7
PubMed 10429623
Chemotherapy in osteosarcoma - The Scandinavian Sarcoma Group experience
Acta Orthop. Scand., 70 285, 74-82
DOI 10.1080/17453674.1999.11744828
Chemotherapy in osteosarcoma. The Scandinavian Sarcoma Group experience
Acta Orthop Scand Suppl, 285, 74-82
PubMed 10429627
Clinical course in synovial sarcoma: a Scandinavian sarcoma group study of 104 patients
Acta Orthop Scand, 70 (6), 536-42
DOI 10.3109/17453679908997839, PubMed 10665716
Dynamic bone scintigraphy for evaluation of tumor response after preoperative chemotherapy. A retrospective study of osteosarcoma and Ewing's sarcoma patients
Acta Orthop Scand Suppl, 285, 11-7
DOI 10.1080/17453674.1999.11744817, PubMed 10429616
Publications 1998
Molecular characterization of a novel amplicon at 1q21-q22 frequently observed in human sarcomas
Br J Cancer, 78 (4), 495-503
DOI 10.1038/bjc.1998.521, PubMed 9716033
Ewing's sarcoma treatment in Scandinavia 1984-1990--ten-year results of the Scandinavian Sarcoma Group Protocol SSGIV
Acta Oncol, 37 (4), 375-8
DOI 10.1080/028418698430601, PubMed 9743460
Publications 1997
The role of pulmonary metastasectomy for soft tissue sarcoma
Acta Orthop Scand Suppl, 273, 145-7
DOI 10.1080/17453674.1997.11744721, PubMed 9057606
Continuous intratumoral microdialysis during high-dose methotrexate therapy in a patient with malignant fibrous histiocytoma of the femur: a case report
Cancer Chemother Pharmacol, 39 (3), 267-72
DOI 10.1007/s002800050571, PubMed 8996531
Chemotherapy for adult soft tissue sarcoma. Does it work?
Acta Orthop Scand Suppl, 273, 139-44
PubMed 9057605
Chemotherapy for adult soft tissue sarcoma - Does it work?
Acta Orthop. Scand., 68 273, 139-144
DOI 10.1080/17453674.1997.11744720
Chemotherapy for osteosarcoma and Ewing's sarcoma
Acta Orthop Scand Suppl, 273, 120-5
DOI 10.1080/17453674.1997.11744716, PubMed 9057601
Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group Phase II Study
Eur J Cancer, 33 (10), 1551-8
DOI 10.1016/s0959-8049(97)00102-0, PubMed 9389914
Prognostic factors in bone sarcomas
Acta Orthop Scand Suppl, 273, 156-60
DOI 10.1080/17453674.1997.11744723, PubMed 9057608
The outcome of advanced soft tissue sarcoma patients with complete tumour regression after either chemotherapy alone or chemotherapy plus surgery. The Scandinavian Sarcoma Group experience
Eur J Cancer, 33 (3), 357-61
DOI 10.1016/s0959-8049(97)89006-5, PubMed 9155517
Publications 1996
Skin lesions and G-CSF in patients with malignant diseases. Malignancy or cutaneous side-effect?
Eur J Cancer, 32A (3), 554-5
DOI 10.1016/0959-8049(95)00595-1, PubMed 8814708
Gain of 17q24-qter detected by comparative genomic hybridization in malignant tumors from patients with von Recklinghausen's neurofibromatosis
Cancer Res, 56 (20), 4778-81
PubMed 8840998
Extremity and non-extremity high-grade osteosarcoma -- the Norwegian Radium Hospital experience during the modern chemotherapy era
Acta Oncol, 35 Suppl 8, 129-34
DOI 10.3109/02841869609098531, PubMed 9073059
Publications 1995
Alterations at chromosome 17 loci in peripheral nerve sheath tumors
J Neuropathol Exp Neurol, 54 (1), 65-73
DOI 10.1097/00005072-199501000-00008, PubMed 7815081
Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival
Cancer, 75 (5), 1084-93
DOI 10.1002/1097-0142(19950301)75:5<1084::aid-cncr2820750506>3.0.co;2-f, PubMed 7850705
Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide
Cancer Chemother Pharmacol, 36 (2), 172-5
DOI 10.1007/BF00689204, PubMed 7539339
Intracranial primary leiomyosarcoma arising in a teratoma of the pineal area
Clin Neuropathol, 14 (4), 245-8
PubMed 8521631
Publications 1994
Proliferation of diploid hepatocytes and nonparenchymal (oval) cells during rat-liver regeneration in the presence of 2-acetylaminofluorene
Int J Oncol, 5 (4), 805-10
DOI 10.3892/ijo.5.4.805, PubMed 21559645
[Treatment of chondrosarcoma. A retrospective study at the Norwegian Radium Hospital]
Tidsskr Nor Laegeforen, 114 (26), 3075-8
PubMed 7974427
Publications 1993
Genetic alterations in a malignant schwannoma from a patient with neurofibromatosis (NF1)
Pathol Res Pract, 189 (4), 465-71; discussion 471-4
DOI 10.1016/S0344-0338(11)80339-0, PubMed 8351250
[Diagnostic aspects of subacute osteomyelitis in children and adolescents. Clinical and radiographic resemblance to primary malignant tumors]
Tidsskr Nor Laegeforen, 113 (26), 3240-3
PubMed 8236217
Publications 1992
The treatment of osteosarcoma: present trends. The Scandinavian Sarcoma Group experience
Ann Oncol, 3 Suppl 2, S7-11
DOI 10.1093/annonc/3.suppl_2.s7, PubMed 1622872
High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study
Br J Cancer, 65 (6), 956-60
DOI 10.1038/bjc.1992.200, PubMed 1616870
Publications 1991
Osteogenic sarcoma: MR signal abnormalities of the brain in asymptomatic patients treated with high-dose methotrexate
Radiology, 179 (2), 547-50
DOI 10.1148/radiology.179.2.2014309, PubMed 2014309
Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study
J Clin Oncol, 9 (10), 1766-75
DOI 10.1200/JCO.1991.9.10.1766, PubMed 1717666
Diploid growth pattern of hepatocellular tumours induced by various carcinogenic treatments
Carcinogenesis, 12 (2), 325-7
DOI 10.1093/carcin/12.2.325, PubMed 1847321
Publications 1990
Management of patients with poor-prognosis nonseminomatous germ cell cancer
Oncology, 47 (3), 234-40
DOI 10.1159/000226822, PubMed 1692984
Cell biology of hepatocarcinogenesis
Crit Rev Oncog, 1 (4), 437-66
PubMed 1964598
Liver tumor promoters stimulate growth of transplanted hepatocellular carcinomas
Hepatology, 12 (2), 295-300
DOI 10.1002/hep.1840120217, PubMed 2167869
Publications 1989
Diploid nature of hepatocellular tumours developing from transplanted preneoplastic liver cells
Br J Cancer, 59 (2), 198-205
DOI 10.1038/bjc.1989.41, PubMed 2930686
Neuroendocrine dysdifferentiation and bombesin production in carcinogen-induced hepatocellular rat tumours
Carcinogenesis, 10 (1), 21-5
DOI 10.1093/carcin/10.1.21, PubMed 2910524
Publications 1988
Changes in ploidy distributions in human liver carcinogenesis
J Natl Cancer Inst, 80 (18), 1480-5
DOI 10.1093/jnci/80.18.1480, PubMed 2846856
Shift from polyploidizing to nonpolyploidizing growth in carcinogen-treated rat liver
J Natl Cancer Inst, 80 (12), 950-8
DOI 10.1093/jnci/80.12.950, PubMed 3398071
The polyploidizing growth pattern of normal rat liver is replaced by divisional, diploid growth in hepatocellular nodules and carcinomas
Carcinogenesis, 9 (6), 939-45
DOI 10.1093/carcin/9.6.939, PubMed 3370757
2-Acetylaminofluorene promotion of liver carcinogenesis by a non-cytotoxic mechanism
Carcinogenesis, 9 (4), 581-7
DOI 10.1093/carcin/9.4.581, PubMed 2895691
Publications 1987
Progressive loss of vision in patients with high-grade non-Hodgkin's lymphoma
Cancer, 60 (10), 2521-3
DOI 10.1002/1097-0142(19871115)60:10<2521::aid-cncr2820601029>3.0.co;2-n, PubMed 3664433
Gynaecomastia following cytotoxic therapy for testicular cancer
Br J Urol, 59 (4), 348-52
DOI 10.1111/j.1464-410x.1987.tb04647.x, PubMed 3107651
Transplantation of preneoplastic rat hepatocytes by intraportal injection
Toxicol Pathol, 15 (1), 78-81
DOI 10.1177/019262338701500110, PubMed 3554470
Publications 1986
Fifty-five patient years' experience with a totally implanted system for intravenous chemotherapy
Cancer, 57 (6), 1124-9
DOI 10.1002/1097-0142(19860315)57:6<1124::aid-cncr2820570611>3.0.co;2-d, PubMed 3943036
[Implanted subcutaneous injection port. When is continuous venous access needed]
Tidsskr Nor Laegeforen, 106 (7), 577-9
PubMed 3961785
Changes in cellular ploidy and autophagic responsiveness during rat liver carcinogenesis
Toxicol Pathol, 14 (3), 342-8
DOI 10.1177/019262338601400309, PubMed 3787117
Publications 1985
[Calcitonin as an analgesic agent in the treatment of skeletal metastases]
Tidsskr Nor Laegeforen, 105 (26), 1782-4
PubMed 2414858
Publications 1984
Carcinoma of the prostate with soft tissue or non-regional lymphatic metastases at the time of diagnosis: a review of 47 cases
Br J Urol, 56 (4), 385-90
DOI 10.1111/j.1464-410x.1984.tb05827.x, PubMed 6534426
Publications 1983
[Extravasal injection of cytostatics. Special reference to adriamiycin]
Tidsskr Nor Laegeforen, 103 (33), 2260-2
PubMed 6658755